JP2018524013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524013A5 JP2018524013A5 JP2018502637A JP2018502637A JP2018524013A5 JP 2018524013 A5 JP2018524013 A5 JP 2018524013A5 JP 2018502637 A JP2018502637 A JP 2018502637A JP 2018502637 A JP2018502637 A JP 2018502637A JP 2018524013 A5 JP2018524013 A5 JP 2018524013A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- chirally pure
- backbone
- oligonucleotide
- pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 26
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 8
- 230000024203 complement activation Effects 0.000 claims 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 238000004132 cross linking Methods 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- -1 phosphorothioate diester Chemical class 0.000 claims 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021134582A JP7441816B2 (ja) | 2015-07-22 | 2021-08-20 | オリゴヌクレオチド組成物およびその方法 |
| JP2023207761A JP2024028927A (ja) | 2015-07-22 | 2023-12-08 | オリゴヌクレオチド組成物およびその方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195779P | 2015-07-22 | 2015-07-22 | |
| US62/195,779 | 2015-07-22 | ||
| US201562236847P | 2015-10-02 | 2015-10-02 | |
| US62/236,847 | 2015-10-02 | ||
| US201662331960P | 2016-05-04 | 2016-05-04 | |
| US62/331,960 | 2016-05-04 | ||
| PCT/US2016/043598 WO2017015575A1 (en) | 2015-07-22 | 2016-07-22 | Oligonucleotide compositions and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021134582A Division JP7441816B2 (ja) | 2015-07-22 | 2021-08-20 | オリゴヌクレオチド組成物およびその方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524013A JP2018524013A (ja) | 2018-08-30 |
| JP2018524013A5 true JP2018524013A5 (OSRAM) | 2019-08-29 |
| JP7296724B2 JP7296724B2 (ja) | 2023-06-23 |
Family
ID=57835219
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502637A Active JP7296724B2 (ja) | 2015-07-22 | 2016-07-22 | オリゴヌクレオチド組成物およびその方法 |
| JP2018502647A Pending JP2018525357A (ja) | 2015-07-22 | 2016-07-22 | オリゴヌクレオチド組成物およびその方法 |
| JP2021134582A Active JP7441816B2 (ja) | 2015-07-22 | 2021-08-20 | オリゴヌクレオチド組成物およびその方法 |
| JP2021170541A Active JP7606954B2 (ja) | 2015-07-22 | 2021-10-18 | オリゴヌクレオチド組成物およびその方法 |
| JP2023207761A Pending JP2024028927A (ja) | 2015-07-22 | 2023-12-08 | オリゴヌクレオチド組成物およびその方法 |
| JP2024219444A Pending JP2025038091A (ja) | 2015-07-22 | 2024-12-13 | オリゴヌクレオチド組成物およびその方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502647A Pending JP2018525357A (ja) | 2015-07-22 | 2016-07-22 | オリゴヌクレオチド組成物およびその方法 |
| JP2021134582A Active JP7441816B2 (ja) | 2015-07-22 | 2021-08-20 | オリゴヌクレオチド組成物およびその方法 |
| JP2021170541A Active JP7606954B2 (ja) | 2015-07-22 | 2021-10-18 | オリゴヌクレオチド組成物およびその方法 |
| JP2023207761A Pending JP2024028927A (ja) | 2015-07-22 | 2023-12-08 | オリゴヌクレオチド組成物およびその方法 |
| JP2024219444A Pending JP2025038091A (ja) | 2015-07-22 | 2024-12-13 | オリゴヌクレオチド組成物およびその方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US10479995B2 (OSRAM) |
| EP (3) | EP3324978A4 (OSRAM) |
| JP (6) | JP7296724B2 (OSRAM) |
| KR (1) | KR20180028516A (OSRAM) |
| CN (3) | CN108025089A (OSRAM) |
| AU (3) | AU2016297155B2 (OSRAM) |
| BR (1) | BR112017028636A2 (OSRAM) |
| CA (1) | CA2989682A1 (OSRAM) |
| CL (1) | CL2018000145A1 (OSRAM) |
| CO (1) | CO2018001484A2 (OSRAM) |
| CR (1) | CR20180107A (OSRAM) |
| EC (1) | ECSP18010463A (OSRAM) |
| HK (2) | HK1255369A1 (OSRAM) |
| IL (2) | IL320434A (OSRAM) |
| MA (1) | MA43072A (OSRAM) |
| MX (2) | MX2018000796A (OSRAM) |
| NI (1) | NI201800009A (OSRAM) |
| PE (1) | PE20181174A1 (OSRAM) |
| PH (1) | PH12018500145A1 (OSRAM) |
| SG (1) | SG10201912900XA (OSRAM) |
| SV (1) | SV2018005619A (OSRAM) |
| TW (1) | TW201707711A (OSRAM) |
| WO (2) | WO2017015555A1 (OSRAM) |
Families Citing this family (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| IN2012DN00720A (OSRAM) | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
| WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
| MX347361B (es) | 2011-07-19 | 2017-04-12 | Wave Life Sciences Ltd | Metodos para la sintesis de acidos nucleicos funcionalizados. |
| WO2013148260A1 (en) | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| EP2872147B1 (en) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
| EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| TW202246503A (zh) | 2013-07-19 | 2022-12-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| CN106068325B (zh) | 2014-01-16 | 2021-07-09 | 波涛生命科学有限公司 | 手性设计 |
| JP6689279B2 (ja) * | 2014-12-16 | 2020-05-20 | ロシュ イノベーション センター コペンハーゲン エーエス | キラル毒性のスクリーニング方法 |
| WO2016097212A1 (en) | 2014-12-17 | 2016-06-23 | Proqr Therapeutics Ii B.V. | Targeted rna editing |
| US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
| JP6892433B2 (ja) | 2015-04-03 | 2021-06-23 | ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | 十分に安定化された非対称ｓｉｒｎａ |
| DK3277814T3 (da) | 2015-04-03 | 2020-08-24 | Univ Massachusetts | Oligonukleotidforbindelser til målretning mod huntingtin-mrna |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| JP7511326B2 (ja) | 2015-10-09 | 2024-07-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物およびその方法 |
| KR102488323B1 (ko) | 2015-12-10 | 2023-01-12 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| JP7749201B6 (ja) | 2016-01-31 | 2025-10-21 | ユニバーシティー オブ マサチューセッツ | 分岐オリゴヌクレオチド |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| MA45270A (fr) * | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| CN109477103A (zh) | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
| WO2018031933A2 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| NZ751483A (en) | 2016-09-01 | 2022-07-01 | Proqr Therapeutics Ii Bv | Chemically modified single-stranded rna-editing oligonucleotides |
| JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
| JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| EP3554553B1 (en) | 2016-12-19 | 2022-07-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| KR20240006023A (ko) | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| CA3047010A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| WO2018134301A1 (en) | 2017-01-19 | 2018-07-26 | Proqr Therapeutics Ii B.V. | Oligonucleotide complexes for use in rna editing |
| WO2018145009A1 (en) * | 2017-02-06 | 2018-08-09 | University Of Tennessee Research Foundation | Dna-zyme based methods & compositions for treating huntington's disease |
| US11932856B2 (en) | 2017-03-03 | 2024-03-19 | The Regents Of The University Of California | RNA targeting of mutations via suppressor tRNAs and deaminases |
| TW201904587A (zh) | 2017-06-02 | 2019-02-01 | 新加坡商波濤生命科學有限公司 | 寡核苷酸組合物及其使用方法 |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| CN111051281A (zh) | 2017-06-21 | 2020-04-21 | 波涛生命科学有限公司 | 用于合成的化合物、组合物和方法 |
| US10844377B2 (en) | 2017-06-23 | 2020-11-24 | University Of Massachusetts | Two-tailed self-delivering siRNA |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| JP2020534253A (ja) * | 2017-08-08 | 2020-11-26 | ウェーブ ライフ サイエンシーズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| KR20200052369A (ko) | 2017-09-18 | 2020-05-14 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 제조 기술 |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| US20200248178A1 (en) | 2017-09-28 | 2020-08-06 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| US20210145852A1 (en) | 2017-09-28 | 2021-05-20 | Sarepta Therapeutics, Inc. | Combination Therapies for Treating Muscular Dystrophy |
| JP2020536057A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| US11596646B2 (en) | 2017-10-12 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| WO2019140231A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| AU2019208011B2 (en) | 2018-01-12 | 2025-06-05 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| CA3088522A1 (en) | 2018-01-15 | 2019-07-18 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
| US11332733B2 (en) | 2018-02-12 | 2022-05-17 | lonis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| US11661601B2 (en) | 2018-03-22 | 2023-05-30 | Ionis Pharmaceuticals, Inc. | Methods for modulating FMR1 expression |
| US12103926B2 (en) | 2018-03-27 | 2024-10-01 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| EP3775203A4 (en) * | 2018-04-12 | 2022-03-30 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF |
| SG11202010910QA (en) | 2018-05-07 | 2020-12-30 | Alnylam Pharmaceuticals Inc | Extrahepatic delivery |
| UY38225A (es) | 2018-05-09 | 2019-11-29 | Ionis Pharmaceuticals Inc | Compuestos y métodos para reducir de la expresión de atxn3 |
| CU20200082A7 (es) | 2018-05-09 | 2021-06-08 | Ionis Pharmaceuticals Inc | Compuestos y métodos para la reducción de la expresión de fxi |
| AU2019265904A1 (en) | 2018-05-11 | 2020-11-12 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| WO2019226990A1 (en) * | 2018-05-25 | 2019-11-28 | New York Institute Of Technology | Direct nucleic acid sequencing method |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP4219717A3 (en) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| WO2019241648A1 (en) * | 2018-06-14 | 2019-12-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing stmn2 expression |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
| CN109030440B (zh) * | 2018-07-18 | 2020-12-04 | 西北农林科技大学 | 一种基于三氧化钼量子点检测单宁酸含量的方法 |
| EP3826645A4 (en) | 2018-07-25 | 2023-05-17 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION |
| TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| KR20210093227A (ko) | 2018-08-10 | 2021-07-27 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 변형된 올리고뉴클레오티드 |
| WO2020041769A1 (en) | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| TWI869213B (zh) | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| WO2020072883A1 (en) * | 2018-10-05 | 2020-04-09 | Ionis Pharmaceuticals, Inc. | Chirally enriched oligomeric compounds |
| EP3880821A4 (en) | 2018-11-15 | 2023-01-25 | Ionis Pharmaceuticals, Inc. | IRF5 EXPRESSION MODULATORS |
| TWI841633B (zh) | 2018-11-21 | 2024-05-11 | 美商Ionis製藥公司 | 用於減少朊病毒表現之化合物及方法 |
| US12485136B2 (en) | 2018-12-03 | 2025-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity |
| EA202191601A1 (ru) | 2018-12-13 | 2022-01-19 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| IL283967B2 (en) | 2018-12-21 | 2025-03-01 | Ionis Pharmaceuticals Inc | Modulators of hsd17b13 expression |
| WO2020150636A1 (en) | 2019-01-18 | 2020-07-23 | University Of Massachusetts | Dynamic pharmacokinetic-modifying anchors |
| CA3126845A1 (en) * | 2019-02-01 | 2020-08-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| KR20210134686A (ko) | 2019-02-27 | 2021-11-10 | 아이오니스 파마수티컬즈, 인코포레이티드 | Malat1 발현의 조절인자 |
| US20230089442A1 (en) * | 2019-03-20 | 2023-03-23 | Pachamuthu Kandasamy | Technologies useful for oligonucleotide preparation |
| TWI874376B (zh) | 2019-03-29 | 2025-03-01 | 美商Ionis製藥公司 | 用於調節ube3a-ats 之化合物及方法 |
| JP2022528725A (ja) | 2019-04-18 | 2022-06-15 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを治療するための組成物 |
| US20250051778A1 (en) * | 2019-04-25 | 2025-02-13 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US20230145795A1 (en) * | 2019-04-25 | 2023-05-11 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| PT3976791T (pt) | 2019-05-28 | 2025-06-26 | Ionis Pharmaceuticals Inc | Compostos e métodos para reduzir a expressão da fus |
| EP3956450B1 (en) | 2019-07-26 | 2025-08-13 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
| MX2022001710A (es) | 2019-08-09 | 2022-05-10 | Univ Massachusetts | Oligonucleótidos modificados químicamente dirigidos a los snp. |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| EP4045062A1 (en) | 2019-10-14 | 2022-08-24 | Astrazeneca AB | Modulators of pnpla3 expression |
| MX2022005254A (es) | 2019-11-01 | 2022-06-29 | Novartis Ag | El uso de un modulador de empalme para un tratamiento que retrasa la progresion de la enfermedad de huntington. |
| AU2020395113A1 (en) | 2019-12-02 | 2022-06-09 | Shape Therapeutics Inc. | Therapeutic editing |
| CA3172336A1 (en) * | 2020-02-21 | 2021-08-26 | Ionis Pharmaceuticals, Inc | Methods for reducing htt expression |
| BR112022016238A2 (pt) | 2020-02-28 | 2022-10-11 | Ionis Pharmaceuticals Inc | Compostos e métodos para modular smn2 |
| KR20230005194A (ko) * | 2020-03-30 | 2023-01-09 | 알닐람 파마슈티칼스 인코포레이티드 | 미세소관 관련된 단백질 TAU (MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| CA3176196A1 (en) | 2020-04-21 | 2021-10-28 | Flagship Pioneering, Inc. | Bifunctional molecules and methods of using thereof |
| EP4153747A2 (en) | 2020-05-22 | 2023-03-29 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
| AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
| TW202227102A (zh) | 2020-09-22 | 2022-07-16 | 瑞典商阿斯特捷利康公司 | 治療脂肪肝病之方法 |
| WO2022109139A1 (en) | 2020-11-18 | 2022-05-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| TW202305132A (zh) | 2021-03-08 | 2023-02-01 | 法商施維雅藥廠 | 用於抑制α-突觸核蛋白表達之反義寡核苷酸 |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| CN113122615B (zh) * | 2021-05-24 | 2024-07-09 | 湖南赛哲智造科技有限公司 | 一种应用于绝对定量高通量测序的多重pcr扩增的单分子标签引物及其应用 |
| CA3223844A1 (en) | 2021-06-22 | 2022-12-29 | Wen-Hsuan Chang | Pikfyve antisense oligonucleotides |
| IL309334A (en) | 2021-06-23 | 2024-02-01 | Univ Massachusetts | Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders |
| WO2023004049A1 (en) | 2021-07-21 | 2023-01-26 | AcuraStem, Inc. | Unc13a antisense oligonucleotides |
| US20240425864A1 (en) | 2021-09-30 | 2024-12-26 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| MX2024004011A (es) | 2021-10-01 | 2024-07-01 | Adarx Pharmaceuticals Inc | Composiciones moduladoras de precalicreína y métodos de uso de estas. |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| CA3256609A1 (en) | 2022-04-28 | 2023-11-02 | AcuraStem Incorporated | ANTISENSE OLIGONUCLEOTIDES SYF2 |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| CN120476205A (zh) * | 2022-08-11 | 2025-08-12 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| IL319629A (en) | 2022-09-23 | 2025-05-01 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing MECP2 expression |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| KR20250113455A (ko) | 2022-11-24 | 2025-07-25 | 프로큐알 테라퓨틱스 Ⅱ 비.브이. | 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| KR20250115388A (ko) | 2022-12-09 | 2025-07-30 | 프로큐알 테라퓨틱스 Ⅱ 비.브이. | 심혈관 질환 치료용 안티센스 올리고뉴클레오타이드 |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4652276A2 (en) | 2023-01-20 | 2025-11-26 | AcuraStem Incorporated | Unc13a antisense oligonucleotides |
| CN120603947A (zh) | 2023-01-31 | 2025-09-05 | 阿库拉斯特姆公司 | Syf2反义寡核苷酸 |
| WO2024167945A1 (en) | 2023-02-06 | 2024-08-15 | AcuraStem Incorporated | Pikfyve antisense oligonucleotides |
| EP4669753A1 (en) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2024200472A1 (en) | 2023-03-27 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024220930A2 (en) | 2023-04-20 | 2024-10-24 | Adarx Pharmaceuticals, Inc. | Mapt-modulating compositions and methods of use thereof |
| WO2024227040A1 (en) | 2023-04-27 | 2024-10-31 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of chronic kidney disease |
| WO2024238396A1 (en) | 2023-05-12 | 2024-11-21 | Adarx Pharmaceuticals, Inc. | Nmda ligand conjugated compounds and uses thereof |
| AU2024279767A1 (en) | 2023-05-26 | 2025-12-04 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2024263694A1 (en) | 2023-06-20 | 2024-12-26 | Adarx Pharmaceuticals, Inc. | Lrrk2-modulating compositions and methods of use thereof |
| WO2025015335A1 (en) | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025036916A1 (en) | 2023-08-16 | 2025-02-20 | Les Laboratoires Servier | Oligonucleotides for modulating kcnt1 expression |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| US20250243487A1 (en) | 2023-09-14 | 2025-07-31 | Ionis Pharmaceuticals, Inc. | Compounds and Methods for Reducing APOCIII Expression |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| GB202314724D0 (en) | 2023-09-26 | 2023-11-08 | Astrazeneca Ab | compounds and methods for reducing psd3 expression |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
Family Cites Families (211)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US513030A (en) | 1894-01-16 | Machine for waxing or coating paper | ||
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| DE3329892A1 (de) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| US5130300A (en) | 1986-03-07 | 1992-07-14 | Monsanto Company | Method for enhancing growth of mammary parenchyma |
| CA1340032C (en) | 1987-06-24 | 1998-09-08 | Jim Haralambidis | Lucleoside derivatives |
| US4923901A (en) | 1987-09-04 | 1990-05-08 | Millipore Corporation | Membranes with bound oligonucleotides and peptides |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5141813A (en) | 1989-08-28 | 1992-08-25 | Clontech Laboratories, Inc. | Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| CA2029273A1 (en) | 1989-12-04 | 1991-06-05 | Christine L. Brakel | Modified nucleotide compounds |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5457191A (en) | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5614617A (en) | 1990-07-27 | 1997-03-25 | Isis Pharmaceuticals, Inc. | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5512668A (en) * | 1991-03-06 | 1996-04-30 | Polish Academy Of Sciences | Solid phase oligonucleotide synthesis using phospholane intermediates |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US20020183502A1 (en) | 1991-05-21 | 2002-12-05 | Mesmaeker Alain De | Backbone-modified oligonucleotide analogs and methods for using same |
| JP2693643B2 (ja) | 1991-10-15 | 1997-12-24 | アイシス・ファーマシューティカルス・インコーポレーテッド | キラルリン結合を有するオリゴヌクレオチド |
| ES2103918T3 (es) | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios. |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| DK0618925T4 (da) | 1991-12-24 | 2012-07-09 | Isis Pharmaceuticals Inc | Antisense-oligonukleotider |
| US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| KR960705837A (ko) | 1993-11-16 | 1996-11-08 | 라이오넬 엔. 사이몬 | 비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 합성 올리고머(Synthetic Oligomers Having Chirally Pure Phosphonate Internucleosidyl Linkages Mixed with Non-Phosphonate Internucleosidyl Linkages) |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| US6222025B1 (en) | 1995-03-06 | 2001-04-24 | Isis Pharmaceuticals, Inc. | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
| US6639062B2 (en) | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
| US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| AU8512598A (en) | 1997-07-25 | 1999-02-16 | Hybridon, Inc. | Oligonuclotides having 3' terminal stereospecific phosphorothioates |
| US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
| US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
| PT1054693E (pt) * | 1998-02-20 | 2009-01-22 | Genentech Inc | Inibidores da activação do complemento |
| US7045610B2 (en) | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
| US6242589B1 (en) * | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
| US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
| US6066500A (en) | 1999-06-25 | 2000-05-23 | Isis Pharmaceuticals Inc. | Antisense modulation of Beta catenin expression |
| US6147200A (en) | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| US20020082227A1 (en) | 1999-09-30 | 2002-06-27 | Scott Henry | Use of oligonucleotides for inhibition of complement activation |
| US20010055761A1 (en) | 1999-10-29 | 2001-12-27 | Agilent Technologies | Small scale dna synthesis using polymeric solid support with functionalized regions |
| DE10019756A1 (de) | 2000-04-20 | 2001-10-25 | Bayer Ag | Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen |
| US6492171B2 (en) | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
| GB0024752D0 (en) | 2000-10-10 | 2000-11-22 | Univ Belfast | Oxidative halogenation of aromatic compounds |
| US20050277133A1 (en) | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| US6440739B1 (en) | 2001-07-17 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of glioma-associated oncogene-2 expression |
| JP4348044B2 (ja) | 2002-02-12 | 2009-10-21 | 株式会社キラルジェン | 立体規則性の高いジヌクレオシドホスホロチオエートの製造法 |
| US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| HUE037352T2 (hu) | 2002-04-05 | 2018-08-28 | Roche Innovation Ct Copenhagen As | A HIF-1alfa expresszálódását módosító oligomer vegyületek |
| EP2333062A1 (en) | 2002-07-10 | 2011-06-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA-interference by single-stranded RNA molecules |
| US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| US7045306B2 (en) | 2003-04-28 | 2006-05-16 | The General Hospital Corporation | Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein |
| US7589189B2 (en) | 2003-05-14 | 2009-09-15 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| WO2005023828A1 (ja) | 2003-09-02 | 2005-03-17 | Takeshi Wada | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 |
| JP4616175B2 (ja) | 2003-09-02 | 2011-01-19 | 株式会社キラルジェン | ５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法 |
| ES2485848T3 (es) | 2003-09-12 | 2014-08-14 | University Of Massachusetts | ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función |
| US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
| WO2005070859A1 (ja) | 2004-01-27 | 2005-08-04 | Takeshi Wada | フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005085272A1 (ja) | 2004-03-05 | 2005-09-15 | Takeshi Wada | ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| JP4865544B2 (ja) | 2004-03-25 | 2012-02-01 | 株式会社キラルジェン | 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法 |
| WO2005111057A2 (en) | 2004-04-02 | 2005-11-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing il-10 responses |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| WO2006066260A2 (en) | 2004-12-17 | 2006-06-22 | Thiosense, Inc. | Compositions of and methods for producing phosphorus-chiral monomers and oligomers |
| US20060257912A1 (en) | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
| US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
| EP2062980B1 (en) | 2005-06-28 | 2011-08-31 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin gene. |
| US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
| US8501703B2 (en) | 2005-08-30 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
| JP5111385B2 (ja) | 2005-10-28 | 2013-01-09 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ハンチンチン遺伝子の発現を抑制するための組成物および方法 |
| EP2161038B1 (en) | 2006-01-26 | 2013-12-25 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| US7547684B2 (en) | 2006-05-11 | 2009-06-16 | Isis Pharmaceuticals, Inc. | 5′-modified bicyclic nucleic acid analogs |
| CN101460620B (zh) | 2006-05-31 | 2012-02-15 | 东丽株式会社 | 免疫刺激寡核苷酸及其药物用途 |
| CA2662704A1 (en) | 2006-07-07 | 2008-01-10 | University Of Massachusetts | Rna silencing compositions and methods for the treatment of huntington's disease |
| JP5665317B2 (ja) | 2006-10-18 | 2015-02-04 | アイシス ファーマシューティカルズ， インコーポレーテッド | アンチセンス化合物 |
| WO2008151833A2 (en) | 2007-06-13 | 2008-12-18 | Hochschule Mannheim | Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds |
| DE602007005629D1 (de) | 2007-06-18 | 2010-05-12 | Commissariat Energie Atomique | Reversibles siRNA-Silencing eines mutierten und endogenen Huntington-Wildtypgens und dessen Anwendung zur Behandlung von Morbus Huntington |
| AU2008279509B2 (en) | 2007-07-09 | 2011-07-21 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory RNA (SIMRA) compounds |
| WO2009086558A1 (en) * | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP2011515653A (ja) | 2008-02-04 | 2011-05-19 | ガラパゴス・ナムローゼ・フェンノートシャップ | 神経変性疾患の治療に有用な標的配列及びそれらの同定方法 |
| EP2297341A4 (en) | 2008-05-09 | 2013-01-09 | Univ British Columbia | METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON |
| US8679750B2 (en) * | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
| WO2009143391A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
| WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| KR20110044983A (ko) * | 2008-07-10 | 2011-05-03 | 아카데미쉬 지에켄후이스 비즈 드 유니버시테이트 반 암스테르담 | 보체 길항제 및 그 용도 |
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| US20120264806A1 (en) | 2009-02-06 | 2012-10-18 | Bennett C Frank | Oligomeric compounds and excipients |
| WO2010118263A1 (en) | 2009-04-08 | 2010-10-14 | University Of Massachusetts | Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease |
| IN2012DN00720A (OSRAM) | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
| WO2011015573A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| WO2011015572A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| US8927553B2 (en) * | 2009-08-10 | 2015-01-06 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides and uses thereof |
| CA2931725C (en) | 2009-09-11 | 2021-10-19 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| WO2011034072A1 (ja) | 2009-09-16 | 2011-03-24 | 株式会社キラルジェン | Rna及びその誘導体合成のための新規保護基 |
| US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| EP2534262B1 (en) | 2010-02-08 | 2016-12-14 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| DK2534248T3 (en) | 2010-02-08 | 2018-11-19 | Ionis Pharmaceuticals Inc | SELECTIVE REDUCTION OF ALLELVARIANS |
| WO2011108682A1 (ja) | 2010-03-05 | 2011-09-09 | 国立大学法人 東京大学 | リボヌクレオシドホスホロチオエートの製造方法 |
| JP2011184318A (ja) | 2010-03-05 | 2011-09-22 | Univ Of Tokyo | リボヌクレシドｈ−ボラノホスホネート |
| DK2560687T3 (en) | 2010-04-19 | 2017-09-18 | Nlife Therapeutics S L | Preparations and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types |
| MX2013002048A (es) * | 2010-08-20 | 2013-07-03 | Cerulean Pharma Inc | Conjugados, particulas, composiciones y metodos relacionados. |
| EP3406730B1 (en) | 2010-08-31 | 2022-02-23 | Sirna Therapeutics, Inc. | Novel single chemical entities and methods for delivery of oligonucleotides |
| WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
| EP3260540A1 (en) | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| EP2647644B1 (en) | 2010-11-30 | 2020-09-09 | Wave Life Sciences Japan, Inc. | 2'-o-modified rna |
| EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| WO2012109667A1 (en) | 2011-02-12 | 2012-08-16 | University Of Iowa Research Foundation | Therapeutic compounds |
| CN104271740A (zh) * | 2011-04-20 | 2015-01-07 | L·J·史密斯 | 利用在细胞中自组装和产生RNAi活性的成分来调节基因表达的方法和组合物 |
| MX347361B (es) | 2011-07-19 | 2017-04-12 | Wave Life Sciences Ltd | Metodos para la sintesis de acidos nucleicos funcionalizados. |
| ES2651514T3 (es) | 2011-08-11 | 2018-01-26 | Ionis Pharmaceuticals, Inc. | Compuestos oligoméricos gapados que comprenden deoxirribonucleósidos modificados en 5 ' -en la brecha y usos de ellos |
| JP6317675B2 (ja) | 2011-11-30 | 2018-04-25 | サレプタ セラピューティクス， インコーポレイテッド | 延長リピート病を処置するためのオリゴヌクレオチド |
| CN111893117B (zh) | 2012-01-27 | 2024-06-04 | 比奥马林技术公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| AU2013287630B2 (en) * | 2012-07-13 | 2017-05-25 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| EP2872147B1 (en) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
| US20150275208A1 (en) | 2012-10-12 | 2015-10-01 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| JP2016503394A (ja) | 2012-10-26 | 2016-02-04 | エヌライフ、セラピューティックス、ソシエダッド、リミターダＮｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｓ．Ｌ． | 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法 |
| MX2015005352A (es) | 2012-10-26 | 2015-10-29 | Nlife Therapeutics S L | Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas. |
| WO2014118267A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Lna oligonucleotide carbohydrate conjugates |
| US10260069B2 (en) | 2013-02-04 | 2019-04-16 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| BR112016007255A2 (pt) * | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| JP2016537341A (ja) | 2013-11-11 | 2016-12-01 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ハンチントン病を処置するための方法および組成物 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| CN106068325B (zh) | 2014-01-16 | 2021-07-09 | 波涛生命科学有限公司 | 手性设计 |
| DK3137476T3 (da) | 2014-04-28 | 2019-11-18 | Ionis Pharmaceuticals Inc | Linker-modificerede oligomerforbindelser |
| JP2017515819A (ja) | 2014-05-08 | 2017-06-15 | サンガモ セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための方法および組成物 |
| US9523093B2 (en) | 2014-05-20 | 2016-12-20 | University Of Iowa Research Foundation | Huntington's disease therapeutic compounds |
| US20160017327A1 (en) | 2014-07-11 | 2016-01-21 | The Johns Hopkins University | Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20180112217A1 (en) | 2014-11-19 | 2018-04-26 | Roche Innovation Center Copenhagen A/S | Stereospecific Phosphorothioate LNA |
| JP6689279B2 (ja) | 2014-12-16 | 2020-05-20 | ロシュ イノベーション センター コペンハーゲン エーエス | キラル毒性のスクリーニング方法 |
| KR102636633B1 (ko) | 2014-12-24 | 2024-02-13 | 유니큐어 아이피 비.브이. | 헌팅턴 유전자 억제를 유도하는 RNAi |
| WO2016127002A1 (en) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
| EP3254104B1 (en) | 2015-02-04 | 2021-08-25 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
| MY181458A (en) | 2015-02-10 | 2020-12-22 | Genzyme Corp | Variant rnai |
| DK3277814T3 (da) | 2015-04-03 | 2020-08-24 | Univ Massachusetts | Oligonukleotidforbindelser til målretning mod huntingtin-mrna |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| JP7511326B2 (ja) | 2015-10-09 | 2024-07-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物およびその方法 |
| WO2017067970A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| MA45290A (fr) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2018022473A1 (en) | 2016-07-25 | 2018-02-01 | Wave Life Sciences Ltd. | Phasing |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| TW201904587A (zh) | 2017-06-02 | 2019-02-01 | 新加坡商波濤生命科學有限公司 | 寡核苷酸組合物及其使用方法 |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN120330183A (zh) | 2017-06-02 | 2025-07-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CN111051281A (zh) | 2017-06-21 | 2020-04-21 | 波涛生命科学有限公司 | 用于合成的化合物、组合物和方法 |
| JP2020534253A (ja) | 2017-08-08 | 2020-11-26 | ウェーブ ライフ サイエンシーズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| KR20200052369A (ko) | 2017-09-18 | 2020-05-14 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 제조 기술 |
| US11596646B2 (en) | 2017-10-12 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| EP3775203A4 (en) | 2018-04-12 | 2022-03-30 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2019265904A1 (en) | 2018-05-11 | 2020-11-12 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| SG11202105626TA (en) | 2018-12-06 | 2021-06-29 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| CA3126845A1 (en) | 2019-02-01 | 2020-08-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| US20230089442A1 (en) | 2019-03-20 | 2023-03-23 | Pachamuthu Kandasamy | Technologies useful for oligonucleotide preparation |
| US20220307019A1 (en) | 2019-03-25 | 2022-09-29 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex and use thereof |
| US20230145795A1 (en) | 2019-04-25 | 2023-05-11 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US20250051778A1 (en) | 2019-04-25 | 2025-02-13 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN114502177A (zh) | 2019-05-09 | 2022-05-13 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| JP7766589B2 (ja) | 2019-10-06 | 2025-11-10 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその使用方法 |
| US20240175016A1 (en) | 2019-10-06 | 2024-05-30 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP4114939A4 (en) | 2020-03-01 | 2024-03-20 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF |
| EP4153747A2 (en) | 2020-05-22 | 2023-03-29 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
| WO2021237223A1 (en) | 2020-05-22 | 2021-11-25 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2022046667A1 (en) | 2020-08-24 | 2022-03-03 | Wave Life Sciences Ltd. | Cells and non-human animals engineered to express adar1 and uses thereof |
| WO2022046723A1 (en) | 2020-08-24 | 2022-03-03 | Wave Life Sciences Ltd. | Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays |
| EP4217363A4 (en) | 2020-09-24 | 2024-09-25 | Mayo Foundation for Medical Education and Research | Screening platforms |
| KR20230118716A (ko) | 2020-11-08 | 2023-08-11 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
| CN116507724A (zh) | 2020-11-08 | 2023-07-28 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| EP4404942A2 (en) | 2021-09-26 | 2024-07-31 | Wave Life Sciences Ltd. | Compositions for editing mecp2 transcripts and methods thereof |
| IL311625A (en) | 2021-09-26 | 2024-05-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| CA3236136A1 (en) | 2021-10-27 | 2023-05-04 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP4422645A4 (en) | 2021-10-27 | 2025-12-03 | Wave Life Sciences Ltd | OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS OF USE |
| WO2023154528A1 (en) | 2022-02-11 | 2023-08-17 | Wave Life Sciences Ltd. | Stereoselective technologies for chiral compounds |
| CN119137134A (zh) | 2022-03-02 | 2024-12-13 | 波涛生命科学有限公司 | 寡核苷酸组合物及其用于外显子跳跃的方法 |
| US20250262235A1 (en) | 2022-04-15 | 2025-08-21 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods relating thereto |
| US20250302995A1 (en) | 2022-05-12 | 2025-10-02 | Chikdu Shakti Shivalila | Oligonucleotide compositions and methods thereof |
| CN120476205A (zh) | 2022-08-11 | 2025-08-12 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| WO2025030155A1 (en) | 2023-08-03 | 2025-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
-
0
- MA MA43072A patent/MA43072A/fr unknown
-
2016
- 2016-07-22 HK HK18114508.6A patent/HK1255369A1/zh unknown
- 2016-07-22 EP EP16828617.7A patent/EP3324978A4/en active Pending
- 2016-07-22 AU AU2016297155A patent/AU2016297155B2/en active Active
- 2016-07-22 US US15/746,220 patent/US10479995B2/en active Active
- 2016-07-22 BR BR112017028636A patent/BR112017028636A2/pt not_active IP Right Cessation
- 2016-07-22 SG SG10201912900XA patent/SG10201912900XA/en unknown
- 2016-07-22 HK HK18114509.5A patent/HK1255370A1/zh unknown
- 2016-07-22 EP EP23206565.6A patent/EP4344744A3/en active Pending
- 2016-07-22 EP EP16828604.5A patent/EP3325017A4/en not_active Withdrawn
- 2016-07-22 KR KR1020187004483A patent/KR20180028516A/ko not_active Withdrawn
- 2016-07-22 CN CN201680043299.6A patent/CN108025089A/zh active Pending
- 2016-07-22 IL IL320434A patent/IL320434A/en unknown
- 2016-07-22 WO PCT/US2016/043542 patent/WO2017015555A1/en not_active Ceased
- 2016-07-22 CN CN201680042413.3A patent/CN108135921B/zh active Active
- 2016-07-22 CA CA2989682A patent/CA2989682A1/en active Pending
- 2016-07-22 US US15/746,199 patent/US20180216107A1/en not_active Abandoned
- 2016-07-22 JP JP2018502637A patent/JP7296724B2/ja active Active
- 2016-07-22 PE PE2018000099A patent/PE20181174A1/es unknown
- 2016-07-22 TW TW105123348A patent/TW201707711A/zh unknown
- 2016-07-22 JP JP2018502647A patent/JP2018525357A/ja active Pending
- 2016-07-22 CR CR20180107A patent/CR20180107A/es unknown
- 2016-07-22 MX MX2018000796A patent/MX2018000796A/es unknown
- 2016-07-22 WO PCT/US2016/043598 patent/WO2017015575A1/en not_active Ceased
- 2016-07-22 CN CN202311216358.3A patent/CN117965536A/zh active Pending
-
2017
- 2017-12-26 IL IL256603A patent/IL256603A/en unknown
-
2018
- 2018-01-15 NI NI201800009A patent/NI201800009A/es unknown
- 2018-01-18 CL CL2018000145A patent/CL2018000145A1/es unknown
- 2018-01-18 MX MX2025000894A patent/MX2025000894A/es unknown
- 2018-01-18 PH PH12018500145A patent/PH12018500145A1/en unknown
- 2018-01-22 SV SV2018005619A patent/SV2018005619A/es unknown
- 2018-02-09 EC ECIEPI201810463A patent/ECSP18010463A/es unknown
- 2018-02-15 CO CONC2018/0001484A patent/CO2018001484A2/es unknown
-
2019
- 2019-08-26 US US16/551,503 patent/US20200080083A1/en not_active Abandoned
-
2020
- 2020-02-04 US US16/782,021 patent/US11634710B2/en active Active
-
2021
- 2021-07-14 US US17/375,658 patent/US20220195429A1/en not_active Abandoned
- 2021-08-20 JP JP2021134582A patent/JP7441816B2/ja active Active
- 2021-10-18 JP JP2021170541A patent/JP7606954B2/ja active Active
-
2023
- 2023-02-14 AU AU2023200807A patent/AU2023200807A1/en not_active Abandoned
- 2023-04-21 US US18/305,195 patent/US12486505B2/en active Active
- 2023-12-08 JP JP2023207761A patent/JP2024028927A/ja active Pending
-
2024
- 2024-12-13 JP JP2024219444A patent/JP2025038091A/ja active Pending
-
2025
- 2025-08-25 AU AU2025220872A patent/AU2025220872A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524013A5 (OSRAM) | ||
| WO2017015555A8 (en) | Oligonucleotide compositions and methods thereof | |
| WO2014059353A3 (en) | Oligomeric compounds comprising bicyclic nucleosides and uses thereof | |
| JP2009504138A5 (OSRAM) | ||
| JP2017533710A5 (OSRAM) | ||
| JP2016527313A5 (OSRAM) | ||
| JP2012223202A5 (OSRAM) | ||
| IN2015DN01472A (OSRAM) | ||
| JP2015511818A5 (OSRAM) | ||
| JP2017514467A5 (OSRAM) | ||
| JP2014102578A5 (OSRAM) | ||
| JP2018027138A5 (OSRAM) | ||
| JP2015128433A5 (OSRAM) | ||
| JP2015533791A5 (OSRAM) | ||
| JP2015119721A5 (OSRAM) | ||
| JP2018068317A5 (OSRAM) | ||
| WO2015084884A3 (en) | Antisense compounds and uses thereof | |
| JP2016108250A5 (OSRAM) | ||
| JP2018143674A5 (OSRAM) | ||
| JP2011062136A5 (OSRAM) | ||
| WO2012061726A3 (en) | Compositions and methods for sequencing dna | |
| JP2019136264A5 (OSRAM) | ||
| JP2014188279A5 (OSRAM) | ||
| TWD183172S (zh) | 輪胎鋁圈（三） | |
| TWD196329S (zh) | 襪子（六） |